Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Edwards LifesciencesEW stock surged Friday after the medtech giant hiked its 2025 outlook following a key setback for rival Boston ScientificEW. In May, Boston Sci pulled its transcatheter aortic ...
At the EuroPCR 2025, Edwards Lifesciences EW has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 ...
2025 Financial Outlook: $5.6-$6 billion in total sales; adjusted EPS of $2.40-$2.50. Therapy Growth: TAVR sales projected at $4.1-$4.4 billion (5%-7% growth); TMTT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback